Floatz logo

Pembrolizumab

Testicular Cancer

West China Hospitalmonoclonal_antibodyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Testicular Cancer cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
University Medical Center Groningen
Phase 2/3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Fudan University
Phase 2B
Etarfolatide
Endocyte
Phase 2B
Ifosfamide
Fudan University
Phase 2CCC
Durvalumab
Ludwig Institute for Cancer Research
Phase 1/2CCC

View all 18 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →